Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Elli

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
American Journal of Hematology|July 22, 2014
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net studyIda Martinelli, Valerio De Stefano, Alessandra Carobbio, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Hematological Oncology|February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsGiulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology|April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world dataFrancesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Leukemia|May 20, 2021
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patientsTiziano Barbui, Valerio De Stefano, Alessandra Carobbio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Leukemia Research|June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
American Journal of Hematology|July 22, 2014
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net studyIda Martinelli, Valerio De Stefano, Alessandra Carobbio, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Hematological Oncology|February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsGiulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology|April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world dataFrancesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Leukemia|May 20, 2021
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patientsTiziano Barbui, Valerio De Stefano, Alessandra Carobbio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Leukemia Research|June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Pageof 13